Search

CLX-0921

CLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome p...

Arbaclofen

It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury.

Mirfentanil

Mirfentanil is a derivative of fentanyl that presents high selectivity for the mu opioid receptor.

SNS-032

Ubrogepant

[A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular … [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022.

Otenabant

Otenabant has been investigated for the treatment of Obesity.

αAβ–Gas6

αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). … It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand

Detomidine

Detomidine is an α2-adrenergic agonist that is used as a horse sedative. Normally, it is administered in the salt form, detomidine hydrochloride.

Indopan

It was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.

JB991

In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug will be applied topically on the skin.